BIO announces presenting companies for Investor Forum.

Press Release Summary:



BIO announced initial selection of 2010 presenting companies for the 9th Annual BIO Investor Forum, taking place October 5-6. Forum will feature more than 140 private and public emerging life science company presentations representing new therapeutic and diagnostic companies from around the world. Event will also debut special Discovery Track featuring young companies that have met selection criteria established by BIO and the 2010 BIO Investor Forum advisory committee.



Original Press Release:



BIO Announces Life Sciences Companies Selected to Present at the 9th Annual BIO Investor Forum



Investment, industry leaders focus on financial approaches and opportunities for sustaining and leveraging innovation

WASHINGTON, D.C. - The Biotechnology Industry Organization (BIO) today announced the initial selection of 2010 presenting companies for the 9th Annual BIO Investor Forum, taking place at the Palace Hotel in San Francisco, Calif. on October 5-6.

"Each year, the BIO Investor Forum attracts hundreds of venture and institutional investors who want to see a highly selective roster of private and emerging public life science companies that warrant financing" said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. "Of particular interest for many venture investors, we have created a new Discovery Track of very early stage companies based on input from technology transfer offices, business plan competitions, and venture investors themselves. BIO believes this expanded forum addresses the current industry environment, in which many investors are looking at companies with demonstrable results as well as those much earlier in development."

BIO and the conference advisory committee established the criteria for presenting companies. The advisory committee is comprised of members from top-tier firms focused on investing and banking in the life sciences industry in addition to executives from emerging and leading biotech companies. Following are the members of the 9th Annual BIO Investor Forum Advisory Committee:
  • Guarav Aggarwal, MD, Managing Director, Panorama Capital
  • Brian Atwood, Managing Director, Versant Ventures
  • Hany Awadalla, Managing Director, Rodman & Renshaw, LLC
  • Alexis Borisy, Entrepreneur in Residence, Third Rock Ventures
  • Jim Healy, MD, PhD, General Partner, Managing Director, Sofinnova Ventures
  • Michael King, Jr., Managing Director, Equity Research, Wedbush PacGrow Life Sciences
  • Ron Laufer, MD, MPH, Senior Managing Director, MedImmune Ventures
  • John Leone, Partner, Paul Capital
  • Evan McCulloch, Vice President & Portfolio Manager, Franklin Templeton Investments
  • George Milstein, Managing Director, Life Sciences Mergers and Acquisitions, Wedbush PacGrow Life Sciences
  • David Mott, General Partner, NEA
  • James Sapirstein, RPh, CEO & President, Tobira Therapeutics

    The BIO Investor Forum will feature more than 140 private and public emerging life science company presentations representing new therapeutic and diagnostic companies from around the world.

    The following companies will present at the 9th Annual BIO Investor Forum:

    Advaxis Inc. ADXS

    Affymax Inc AFFY

    Alimera Sciences ALIM

    Allon Therapeutics Inc. TSE: NPC

    Allozyne, Inc.

    Aradigm Corp. OTC: ARDM

    BioRelix, Inc.

    BioSante Pharmaceuticals Inc. BPAX

    Cara Therapeutics, Inc.

    Cell Therapeutics Inc. CTIC

    Cellerant Therapeutics, Inc.

    Cleveland BioLabs, Inc. CBLI

    Constellation Pharmaceuticals, Inc.

    CorMedix Inc. AMEX: CRMD

    Curis Inc. CRIS

    Cyclacel Pharmaceuticals Inc. CYCC

    Cytos Biotechnology AG

    Fate Therapeutics, Inc.

    FivePrime Therapeutics, Inc.

    GlycoMimetics, Inc.

    Idenix Pharmaceuticals Inc. IDIX

    Inimex Pharmaceuticals, Inc.

    LigoCyte Pharmaceuticals, Inc.

    Living Cell Technologies Ltd. ASX:LCT

    Mirna Therapeutics, Inc.

    Nuon Therapeutics, Inc.

    Oncolytics Biotech Inc. ONCY

    Palatin Technologies AMEX: PTN

    PLx Pharma, Inc.

    Relypsa, Inc.

    RXi Pharmaceuticals Corp. RXII

    Sangart, Inc.

    Somaxon Pharmaceuticals Inc. SOMX

    Sucampo Pharmaceuticals, Inc. SCMP

    Syndax Pharmaceuticals, Inc.

    Tengion Inc. TNGN

    Tetraphase Pharmaceuticals, Inc.

    Threshold Pharmaceuticals Inc. THLD

    Tobira Therapeutics

    Tolerx

    Transdel Pharmaceuticals, Inc. OTC: TDLP

    Virdante Pharmaceuticals, Inc.

    Vitae Pharmaceuticals, Inc.

    XOMA Ltd XOMAD

    ZIOPHARM Oncology Inc. ZIOP

    This year's BIO Investor Forum will also debut a special "Discovery Track" featuring young companies that have met the selection criteria established by BIO and the 2010 BIO Investor Forum advisory committee. The following companies will present on the Discovery Track:

    Catena Pharmaceuticals, Inc.

    ConjuGon Inc.

    Diffusion Pharmaceuticals LLC

    Histogen, Inc.

    MabVax Therapeutics, Inc.

    Mithridion, Inc.

    MedDEV Inc.

    NanoCor Therapeutics, Inc.

    Neuraltus Pharmaceuticals Inc.

    NKT Therapeutics Inc.

    Revotar Biopharmaceuticals AG

    Savara Pharmaceuticals

    TxCell S.A

    Zymeworks Inc.

    Additional presenting companies are confirmed each day. For the most up-to-date list, please visit bio.org/investorforum. Registration is complimentary for qualified investors and members of the media.

    About the 9th Annual BIO Investor Forum

    The BIO Investor Forum is a national investor conference featuring private and emerging public companies. The meeting attracts healthcare venture capital and public market investors and research analysts. In addition, the BIO Investor Forum draws business development executives from global pharmaceutical and biotechnology companies.

    About BIO

    BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling "innovations transforming our world." Subscribe to BIOtech Now.
  • All Topics